𝔖 Bobbio Scriptorium

✦ LIBER ✦

Chemotherapy prior to loco-regional treatment has survival benefits for people with cancer of the oropharynx

✍ Scribed by André Eckardt

Book ID: 114483773
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 162 KB
Volume: 2
Category: Article
ISSN: 1363-4054
DOI: 10.1054/ebon.2001.0116

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of B cell lymphoma with chemot

Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry

✍ Stefan W. Krause; Michael Gerken; Reinhard Andreesen; Ferdinand Hofstädter; Moni 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 390 KB

Corrigendum to "Stop-flow technique for

Corrigendum to "Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers" [European Journal of Surgical Oncology 30 (2004) 663–670]

📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Response to chemotherapy has predictive

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party

✍ M Paesmans; J.P Sculier; P Libert; G Bureau; G Dabouis; J Thiriaux; J Michel; O 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Close, but still too far. The experience

Close, but still too far. The experience of Australian people with cancer commuting from a regional to a capital city for radiotherapy treatment

✍ D. HEGNEY; S. PEARCE; C. ROGERS-CLARK; K. MARTIN-MCDONALD; E. BUIKSTRA 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

Pre-operative chemotherapy may improve s

Pre-operative chemotherapy may improve survival for people with oesophageal cancer: Abstracted from: Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone ASl. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754–761.

✍ P Naughton 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 137 KB

High dose therapy may have no survival b

High dose therapy may have no survival benefit over CHOEP primary chemotherapy for people with aggressive non-Hodgkin’s lymphoma: Abstracted from: Kaiser U, Uebelacker I, Birkmann U et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. Journal of Clinical Oncology 2002; 20: 4413–19

✍ Axel Glasmacher 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 80 KB